CD8A and neoplasm: Upon MTX-MP treatment, ascites macrophages and CD8+ T cells exhibited the ability to cytolyze H22 tumor cells in vitro; and the combined PD-1 Ab treatment further enhanced this outcome (Supplementary Fig. S7c, d), concomitant with the increased expression of CD107a (Fig. 7j).